Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of p53 (green) in HeLa cells either left untreated (left panel) or treated with 5uM Camptothecin (right panel) for 20 hours. Formalin fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 10 minutes at room temperature and blocked with 1% Blocker BSA (Product # 37525) for 15 minutes at room temperature. Cells were probed with a p53 monoclonal antibody (Product # MA5-14516) at a dilution of 1:50 for at least 1 hour at room temperature, washed with PBS, and incubated with DyLight 488 goat anti-rabbit IgG secondary antibody (Product # 35552) at a dilution of 1:400 for 30 minutes at room temperature. F-Actin (red) was stained with DyLight 554 Phalloidin (Product # 21834) and nuclei (blue) were stained with Hoechst 33342 dye (Product # 62249). Images were taken on a Thermo Scientific ArrayScan or ToxInsight Instrument at 20X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Rat, Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant human full-length wild type p53 protein|
|Storage buffer||tissue culture supernatant|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Western Blot (WB)||1:10-1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 18 publications below|
MA5-14516 targets p53 in IHC (P), ICC/IF, and WB applications and shows reactivity with human samples. This antibody does not cross-react with mouse in immunofluorescent applications.
The MA5-14516 immunogen is recombinant human full-length wild type p53 protein.
This antibody was orginally validated as part of a Thermo Scientific Cellomics High Content Screening Kit. The antibody sold separately may have slightly different performance and may need to be further optimized for the best results.
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
MA5-14516 was used in immunohistochemistry to attempt to identify prognostic biomarkers in serous ovarian cancer patients treated with neoadjuvant chemotherapy
|Khandakar B,Mathur SR,Kumar L,Kumar S,Datta Gupta S,Iyer VK,Kalaivani M||BioMed research international (2014:null)||2014|
Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
MA5-14516 was used in immunohistochemistry to study ovarian and fallopian tube epithelial expression of gamma-H2AX and p53 in patients with BRCA1 and BRCA2 mutations undergoing salpingo-oophrectomy
|Staff S,Tolonen T,Laasanen SL,Mecklin JP,Isola J,Mäenpää J||International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists (33:309)||2014|
Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
MA5-14516 was used in immunohistochemistry to study the diagnostic value of the immunohistochemical expression of apoptotic and anti-apoptotic markers in serous and mucinous ovarian tumors
|Ozer H,Yenicesu G,Arici S,Cetin M,Tuncer E,Cetin A||Diagnostic pathology (7:null)||2012|
Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.
MA5-14516 was used in immunohistochemistry to study the genetics of mesenchymal, clear cell and dedifferentiated chondrosarcoma and the potential involvement of the retinoblastoma pathway
|Meijer D,de Jong D,Pansuriya TC,van den Akker BE,Picci P,Szuhai K,Bovée JV||Genes, chromosomes & cancer (51:899)||2012|
Proliferation and maturation of microvessels in arteriovenous malformations--expression patterns of angiogenic and cell cycle-dependent factors.
MA5-14516 was used in immunohistochemistry to study the patterns of proliferation and maturation of microvessels in arteriovenous malformations
|Meijer-Jorna LB,van der Loos CM,Teeling P,de Boer OJ,Florquin S,van der Horst CM,van der Wal AC||Journal of cutaneous pathology (39:610)||2012|
Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma.
MA5-14516 was used in immunohistochemistry to study the immunohistochemical expression of p53, p21, p27, cyclin D1 and Ki67 in oral and oropharyngeal squamous cell carcinoma
|Perisanidis C,Perisanidis B,Wrba F,Brandstetter A,El Gazzar S,Papadogeorgakis N,Seemann R,Ewers R,Kyzas PA,Filipits M||Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (41:40)||2012|
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
MA5-14516 was used in immunohistochemistry to identify biomarkers that predict the recurrence of benign meningiomas
|Abdelzaher E,El-Gendi SM,Yehya A,Gowil AG||British journal of neurosurgery (25:707)||2011|
The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas.
MA5-14516 was used in immunohistochemistry to investigate the effect of the cooperating mutation or "second hit" on MYC-induced murine lymphomas
|Schuster C,Berger A,Hoelzl MA,Putz EM,Frenzel A,Simma O,Moritz N,Hoelbl A,Kovacic B,Freissmuth M,Müller M,Villunger A,Müllauer L,Schmatz AI,Streubel B,Porpaczy E,Jäger U,Stoiber D,Sexl V||Blood (118:4635)||2011|
Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
MA5-14516 was used in immunohistochemistry to investigate the possible prognostic value of p53 overexpression in breast cancer patients
|Lee DS,Kim SH,Suh YJ,Kim S,Kim HK,Shim BY||Japanese journal of clinical oncology (41:854)||2011|
Osteosarcoma arising in a long-standing uterine leiomyoma: a case report and literature review.
MA5-14516 was used in immunohistochemistry to report on a case of osteosarcoma occurring in a long-standing uterine leiomyoma
|Wang RC,Wen MC,Wang J,Ho SC,Jan YJ||International journal of surgical pathology (19:99)||2011|
Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.
MA5-14516 was used in immunohistochemistry to study MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres
|Sciuscio D,Diserens AC,van Dommelen K,Martinet D,Jones G,Janzer RC,Pollo C,Hamou MF,Kaina B,Stupp R,Levivier M,Hegi ME||Clinical cancer research : an official journal of the American Association for Cancer Research (17:255)||2011|
Correlation of immunohistochemical expression of p53 with unamplified chromosome 17 polysomy in invasive breast carcinoma.
MA5-14516 was used in immunohistochemistry to study the correlation of p53 expression with unamplified chromosome 17 polysomy in invasive breast carcinoma
|Krishnamurti U,Zarineh A,Atem FD,Silverman JF||Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry (19:28)||2011|
Role of loss of o⁶-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression.
MA5-14516 was used in immunohistochemistry to study the role and prognostic significance of O-methylguanine DNA methyltransferase expression in non-small cell lung carcinoma.
|Myong NH||Cancer research and treatment : official journal of Korean Cancer Association (42:95)||2010|
Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
MA5-14516 was used in immunohistochemistry to determine the prognotic significance of SPARC expression in meningioma
|Bozkurt SU,Ayan E,Bolukbasi F,Elmaci I,Pamir N,Sav A||APMIS : acta pathologica, microbiologica, et immunologica Scandinavica (117:651)||2009|
The comparative effects of pneumoperitoneum on apoptosis and p53 expression in gastrointestinal organs.
MA5-14516 was used in immunohistochemistry to investigate the effect of a novel surgical procedure on the apoptosis and p53 expression in gastrointestinal organs
|Arikan Y,Tosun M,Yilmaz S,Saykol V,Söylemez Z||Journal of laparoendoscopic & advanced surgical techniques. Part A (18:365)||2008|
Expression of senescence-related genes in human corneal endothelial cells.
MA5-14516 was used in immunohistochemistry to study the expression of senescence-related genes in human corneal endothelial cells from donors of different ages
|Song Z,Wang Y,Xie L,Zang X,Yin H||Molecular vision (14:161)||2008|
Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr virus positive and negative pediatric Hodgkin lymphoma.
MA5-14516 was used in immunohistochemistry to evaluate prognostic markers for Epstein-Barr virus positive and negative pediatric Hodgkin lymphoma
|Aktaş S,Kargi A,Olgun N,Diniz G,Erbay A,Vergin C||Lymphatic research and biology (5:175)||2007|
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
MA5-14516 was used in immunohistochemistry to study the involvement of p38alpha MAPK in myeloma cell apoptosis
|Navas TA,Nguyen AN,Hideshima T,Reddy M,Ma JY,Haghnazari E,Henson M,Stebbins EG,Kerr I,O'Young G,Kapoun AM,Chakravarty S,Mavunkel B,Perumattam J,Luedtke G,Dugar S,Medicherla S,Protter AA,Schreiner GF,Anderson KC,Higgins LS||Leukemia (20:1017)||2006|
antigen NY-CO-13; cellular tumor antigen p53; mutant tumor protein 53; p53 tumor suppressor; phosphoprotein p53; TP53; transformation-related protein 53; tumor protein 53; tumor supressor p53
BCC7; LFS1; P53; TP53; TRP53